From a technical perspective, Organon (OGN) is looking like an interesting pick, as it just reached a key level of support. OGN recently overtook the 20- day moving average, and this suggests a short-term bullish trend. The 20-day simple moving average is a popular investing tool. Traders like this SMA because it offers a look back at a stock's price over a shorter period and helps smooth out price fluctuations. The 20-day can also show more trend reversal signals than longer-term moving averages. The 20-da ...

Organon (OGN) could be a solid choice for investors given the company's remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue since analysts are still raising their earnings estimates for the company. The upward trend in estimate revisions for this pharmaceutical company reflects growing optimism of analysts on its earnings prospects, which should get reflected in its stock price. After all, empirical research shows a strong correlation between ...

Which Healthcare Company Is Best? Joe Raedle/Getty Images News Organon (NYSE:OGN) and Pfizer (PFE) both yield over 5% and are the two highest yielding pharmaceuticals. Bristol-Myers (BMY) is the only other pharmaceutical company that offers a yield above 5% that like Organon and Pfizer, can compete with similarly yielding Treasuries (i.e., those with maturities 12 months or less). Three troubling years of declining double-digit annualized returns have resulted in these well-above average yields. Pfizer has ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 10-Q ________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File No. 001-40235 Organon & Co. (Exact name of registrant as specified i ...

Organon (OGN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. The power of a ...

财务数据和关键指标变化 - 第一季度收入为16亿美元,同比增长7%,各业务线均有贡献 [11] - 第一季度调整后EBITDA为5.38亿美元,调整后EBITDA利润率为33.2%,调整后每股收益为1.22美元 [12] - 公司有信心实现2024年全年收入和调整后EBITDA利润率的指引目标 [12] 各条业务线数据和关键指标变化 女性健康业务 - 女性健康业务第一季度增长12%,主要由于Nexplanon销售强劲 [14] - Nexplanon在美国和全球市场均实现两位数增长,预计全年将保持强劲增长势头 [14][15] - 公司有信心Nexplanon到2025年将达到10亿美元的年销售额 [16][18] - 公司认为Nexplanon在美国的专利保护可能延长至2030年 [16][17][18] - 生育业务在中美两大市场表现良好,预计全年将实现高个位数增长 [19] 生物类似药业务 - 生物类似药业务第一季度增长46%,预计2024年将继续实现两位数增长 [20][21] - 公司与上海复宏汉霖合作引进两款生物类似药候选药物,计划在2024年提交监管申请 [23] 成熟品牌业务 - 成熟品牌业务第一季度增长2%,全年预计将保持持平 [24][25] - 新增的两款偏头痛药物Emgality和Rayvow有助于抵消中国带量采购的影响 [24][26] 各个市场数据和关键指标变化 - 美国市场第一季度增长14%,主要由于Nexplanon、Hadlima和Jada表现良好 [26] - 拉美地区第一季度增长36%,主要由于巴西Ontruzant中标带来的机会性销量 [27] - 亚太日本地区第一季度下降7%,预计全年将面临挑战 [28] - 中国市场第一季度下降5%,但预计全年将实现增长 [28] 公司战略和发展方向及行业竞争 - 公司将继续通过业务发展交易拓展女性健康业务范畴,如最近与礼来公司合作引进两款偏头痛药物 [13][31][32] - 公司在生物类似药领域将保持每2年推出一款新品的节奏 [22] - 公司正在推进Nexplanon的生命周期管理,包括获得5年适应症标签和开发新的非激素避孕方法 [30][31][32] 管理层对经营环境和未来前景的评论 - 公司有信心实现2024年的财务目标,包括收入增长和调整后EBITDA利润率维持或改善 [10][12] - 公司有信心Nexplanon未来几年仍有较大增长空间,并预计到2025年将达到10亿美元的年销售额 [16][18] - 公司认为Nexplanon在美国的专利保护可能延长至2030年,不会出现传统的仿制药侵蚀曲线 [16][17][18] - 公司看好生物类似药业务的发展前景,预计2024年将继续实现两位数增长 [20][21] - 公司认为成熟品牌业务将在2024年保持持平的表现 [24][25] 问答环节重要的提问和回答 问题1 **Umer Raffat提问** 关于公司2024年自由现金流的问题,包括季节性波动和未来Nexplanon五年适应症可能带来的影响 [65][66][67][68] **Kevin Ali和Matt Walsh回答** - 公司预计2024年全年自由现金流将达到10亿美元,主要受益于业务表现和一次性成本的下降 [50][51][52][53] - 公司认为Nexplanon五年适应症不会对现金流产生重大负面影响,反而可能带来新的增长机会 [66][67][68] 问题2 **Jason Gerberry提问** 关于公司在Humira仿制药市场的策略和Nexplanon海外专利到期后的市场预期 [95][96][97][98] **Kevin Ali回答** - 公司将继续采取多元化的策略,在PBM渠道和政府/医疗保险等低价渠道同时推广Humira仿制药 [98][99] - 公司认为Nexplanon海外专利到期不会对公司产生重大影响,主要原因是海外市场相对分散,竞争压力较小 [100][101]

Organon (OGN) came out with quarterly earnings of $1.22 per share, beating the Zacks Consensus Estimate of $0.97 per share. This compares to earnings of $1.08 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of 25.77%. A quarter ago, it was expected that this pharmaceutical company would post earnings of $0.80 per share when it actually produced earnings of $0.88, delivering a surprise of 10%. Over the last four quarters, the co ...

Exhibit 99.1 Media Contacts: Karissa Peer Investor Contacts: Jennifer Halchak (614) 314-8094 (201) 275-2711 Kate Vossen Renee McKnight (732) 675-8448 (551) 204-6129 Organon Reports Results for the First Quarter Ended March 31, 2024 • First quarter 2024 revenue of $1,622 million, up 5% on an as-reported basis and 7% at constant currency • First quarter 2024 diluted earnings per share of $0.78 and non-GAAP Adjusted diluted earnings per share of $1.22; both reported and non-GAAP Adjusted diluted earnings per s ...

Organon & Co. (OGN) is scheduled to release first-quarter 2024 results on May 2, before the opening bell. In the last reported quarter, the company’s earnings beat estimates by 10%. It delivered an average earnings surprise of 5.1% in the past four quarters. Q1 Estimates The Zacks Consensus Estimate for revenues is pegged at $1.57 billion. The consensus mark for earnings is pinned at 97 cents per share. Factors to Note Organon’s first quarter witnessed growth in the Women’s Health revenues on the back of st ...

Wall Street analysts forecast that Organon (OGN) will report quarterly earnings of $0.97 per share in its upcoming release, pointing to a year-over-year decline of 10.2%. It is anticipated that revenues will amount to $1.57 billion, exhibiting an increase of 2% compared to the year-ago quarter. The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projection ...